- PTAB · Apr 23, 2025 · IPR2024-01465 · APJ Michelle N Wormmeester · IPR · Institution
The Board denied institution of review of claims 1–19 under § 314(a), finding that the Fintiv factors overall favored discretionary denial.
RulingsInstitution decision- PTAB / AIA Trials › Discretionary denial › Fintiv (parallel litigation)Institution denied fintivInstitution denied
“As noted above, the district court has set a trial date of October 6, 2025, which is almost seven months before the final written decision in this proceeding would be due in late April 2026. Although a number of cases may be scheduled for jury selection on the same day as the District Court Litigation, nothing in the record indicates a trial in the District Court Litigation would not take place months before our deadline to reach a final decision. Because the District Court Litigation will address the issues relating to the validity of the ’750 patent in a trial scheduled to occur several months before we would issue a final written decision, we weigh the second Fintiv factor as favoring discretionary denial.” slip op. at 9
Discretionary denialPatents in suitUS 11,087,750 - PTAB · Apr 23, 2025 · IPR2024-01464 · APJ Michelle N Wormmeester · IPR · Institution
The Board denied institution of inter partes review of claims 1–18 under § 314(a), finding that the Fintiv factors overall favored discretionary denial.
RulingsInstitution decision- PTAB / AIA Trials › Discretionary denial › Fintiv (parallel litigation)Institution denied fintivInstitution denied
“1. whether the court granted a stay or evidence exists that one may be granted if a proceeding is instituted; 2. proximity of the court’s trial date to the Board’s projected statutory deadline for a final written decision; 3. investment in the parallel proceeding by the court and the parties; 4. overlap between issues raised in the petition and in the parallel proceeding; 5. whether the petitioner and the defendant in the parallel proceeding are the same party; and 6. other circumstances that impact the Board’s exercise of discretion, including the merits. Fintiv, Paper 11 at 5–6. In considering these factors, we apply the guidance set forth in a Memorandum regarding “Guidance on USPTO’s recission of ‘Interim Procedure for Discretionary Denials in AIA Post-Grant Proceedings with Parallel District Court Litigation,’” issued by the Chief Administrative Patent Judge of the Patent Trial and Appeal Board on March 24, 2025 (hereinafter, “Guidance Memo”).7” slip op. at 5
Discretionary denialPatents in suitUS 11,393,461 - PTAB · Jun 5, 2024 · IPR2024-00136 · APJ Russell E Cass · IPR · Institution
The Board denied institution of IPR on challenged claim 1 under § 314(a), finding the Fintiv factors favored denial and the petition did not present compelling merits.
RulingsInstitution decision- PTAB / AIA Trials › Discretionary denial › Fintiv (parallel litigation)Institution denied fintivInstitution denied
“Thus, in circumstances where the Board determines that the other Fintiv factors 1–5 do not favor discretionary denial, the Board shall decline to discretionarily deny under Fintiv without reaching the compelling merits analysis. In circumstances where, however, the Board’s analysis of Fintiv factors 1–5 favors denial of institution, the Board shall then assess compelling merits. Id. at 4–5. In this case, Fintiv factors 1–5 favor denial. Specifically, weighing factors 1–5 in this case, we find that the approximately 8-month delay between the estimated trial date and the deadline for a final written decision in this IPR (factor 2), the progress of and investment made by the parties and the Court in the parallel district court case (factor 3), and the fact that Petitioner is also a party in the District Court Litigation (factor 5) outweigh Petitioner’s stipulation mitigating the concerns about overlap between the two proceedings (factor 4). Additionally, we find that factor 1 is neutral. Thus, we address whether the merits of Petitioner’s case are compelling.” slip op. at 19
- PTAB / AIA Trials › Institution threshold (reasonable likelihood / more likely than not)Institution denied meritsInstitution denied
“An inter partes review may not be instituted unless it is determined that “the information presented in the petition filed under section 311 and any response filed under section 313 shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314 (2018); see also 37 C.F.R § 42.4(a) (2021) (“The Board institutes the trial on behalf of the Director.”). The reasonable likelihood standard is “a higher standard than mere notice pleading,” but “lower than the ‘preponderance’ standard to prevail in a final written decision.” Hulu, LLC v. Sound View Innovations, LLC, IPR2018-01039, Paper 29 at 13 (PTAB Dec. 20, 2019) (precedential). For the reasons provided below and based on the record before us, we determine that it is appropriate for us to exercise our discretion under 35 U.S.C. § 314(a) to deny institution in this proceeding. Accordingly, we do not institute an inter partes review based on the Petition.” slip op. at 2
- BurdenNot shown unpatentable
“Based on the present record, Petitioner has not presented a compelling, meritorious case that the challenged claims are unpatentable. Petitioner bases its case upon a claim construction that it ascribes to Patent Owner, and then expressly criticizes as being inconsistent with the plain and ordinary meaning of the claim language and the ’347 patent Specification. Pet. 14–15. Additionally, Petitioner does not provide reasoning or evidence showing why the applied construction is correct, and Patent Owner does not agree with the construction in the Preliminary Response. Id. Under these facts, Petitioner has failed to set forth a sufficient basis for us to find a compelling case of unpatentability. Our conclusion in this regard is consistent with the Board’s prior decisions in Hologic, Orthopediatrics, and Samsung, upon which Patent Owner relies. See Prelim. Resp. 10–14. Moreover, we find that the contrary cases upon which Petitioner relies are inapposite here because they involved alternative constructions advanced by the petitioner. For example, in 10X Genomics, the Board explained that: [E]ven if our rules and guidance were correctly interpreted as prohibiting a petitioner from relying solely on a claim construction it believes is incorrect, that is not what Petitioner has done here. Petitioner proposes alternative claim constructions and presents at least one ground of unpatentability for each construction. 10X Genomics, Paper 8 at 22 (emphasis added). Similarly, in Donnelly, also cited by Petitioner, the petition offered alternative constructions—the construction proposed by the patent owner in district court and the “proper construction” that the petitioner believed was the correct one. Donnelly, Paper 2 (Petition) at 29–33 (identifying alternative constructions of “grip portion”). For the foregoing reasons, we determine that Petitioner has not made a compelling, meritorious showing that “path parameter information,” as required by the challenged claims, is disclosed by or would have been obvious over Sesia. As a result, factor 6 does not weigh in favor of institution.” slip op. at 23
- Claim Construction › Threshold & procedure › Whether a term needs construction (O2 Micro)Other
“Based on the present record, Petitioner has not presented a compelling, meritorious case that the challenged claims are unpatentable. Petitioner bases its case upon a claim construction that it ascribes to Patent Owner, and then expressly criticizes as being inconsistent with the plain and ordinary meaning of the claim language and the ’347 patent Specification. Pet. 14–15. Additionally, Petitioner does not provide reasoning or evidence showing why the applied construction is correct, and Patent Owner does not agree with the construction in the Preliminary Response. Id. Under these facts, Petitioner has failed to set forth a sufficient basis for us to find a compelling case of unpatentability. Our conclusion in this regard is consistent with the Board’s prior decisions in Hologic, Orthopediatrics, and Samsung, upon which Patent Owner relies. See Prelim. Resp. 10–14. Moreover, we find that the contrary cases upon which Petitioner relies are inapposite here because they involved alternative constructions advanced by the petitioner. For example, in 10X Genomics, the Board explained that: [E]ven if our rules and guidance were correctly interpreted as prohibiting a petitioner from relying solely on a claim construction it believes is incorrect, that is not what Petitioner has done here. Petitioner proposes alternative claim constructions and presents at least one ground of unpatentability for each construction. 10X Genomics, Paper 8 at 22 (emphasis added). Similarly, in Donnelly, also cited by Petitioner, the petition offered alternative constructions—the construction proposed by the patent owner in district court and the “proper construction” that the petitioner believed was the correct one. Donnelly, Paper 2 (Petition) at 29–33 (identifying alternative constructions of “grip portion”). For the foregoing reasons, we determine that Petitioner has not made a compelling, meritorious showing that “path parameter information,” as required by the challenged claims, is disclosed by or would have been obvious over Sesia. As a result, factor 6 does not weigh in favor of institution.” slip op. at 23
Claim constructionDiscretionary denialPatents in suitUS 8,891,347
Holdings, summaries, rulings, issues, outcomes, winners and claim constructions shown for a decision were generated by a large language model reading the opinion. They are a guide to the decision, not the decision. Confirm every one against the court's own text before relying on it. Outcomes read from the patent owner’s side. Party names are extracted from the decision and are missing on about 900 short Director denials and scans, which carry the trial number instead.